Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection

Recurrent waves of COVID19 remain a major global health concern. Repurposing either FDA-approved or clinically advanced drug candidates can save time and effort required for validating the safety profile and FDA approval. However, the selection of appropriate screening approaches is key to identifyi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Prabhakaran, Mathayan, Manikannan, Smieszek, Sandra P., Przychodzen, Bartlomiej P., Koprivica, Vuk, Birznieks, Gunther, Polymeropoulos, Mihael H., Prabhakar, Bellur S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108900/
https://www.ncbi.nlm.nih.gov/pubmed/35598394
http://dx.doi.org/10.1016/j.virol.2022.05.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108900/
https://www.ncbi.nlm.nih.gov/pubmed/35598394
http://dx.doi.org/10.1016/j.virol.2022.05.004

Ejemplares similares